Introduction {#s1}
============

Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death among women around the world, accounting for 23% of the new cancer cases and 14% of the cancer deaths in 2008 [@pone.0066519-Jemal1]. In the past 10 years, breast cancer incidence has increased by 20∼30% in China's urban registries [@pone.0066519-Porter1]. It has been implicated that menstrual and reproductive factors are associated with risk of breast cancer among both pre- and post-menopausal women in China [@pone.0066519-Long1]. Except for environmental exposures including lifestyle and behavioral factors, understanding genetic factors related to breast cancer is also important because identifying such factors may be useful for risk prediction. Over the last 5 years, as a powerful method to investigate the genetic determinants of complex diseases, genome-wide association studies (GWAS) have successfully identified more than 20 common susceptibility loci of breast cancer [@pone.0066519-Easton1]--[@pone.0066519-Cai1]. However, most GWAS were conducted in populations of European descent, therefore, it is very necessary to evaluate the generalizability of the GWAS findings in diverse populations across different descents.

Recently, Maya *et al.* carried out a large-scale genome-wide association analysis of breast cancer and further evaluated 72 promising associations in ∼70 000 cases and ∼68 000 controls from 41 case-control studies and 9 breast cancer GWAS. Three new breast cancer susceptibility loci, rs10771399 (12p11), rs1292011 (12q24) and rs2823093 (21q21), were identified in European women, and rs10771399 was also associated with breast cancer risk in Asian women [@pone.0066519-Ghoussaini1]. Following these findings, Antonis *et al.* genotyped rs10771399 and rs1292011 in 12 599 *BRCA1* and 7132 *BRCA2* mutation carriers, and found that rs10771399 near *PTHLH* was also associated with breast cancer risk for *BRCA1* mutation carriers [@pone.0066519-Antoniou1]. To evaluate whether these three new identified variants are also associated with breast cancer risk in Chinese women, we conducted a case--control study with 1792 breast cancer cases and 1867 controls in a Chinese population in Jiangsu province of eastern China.

Materials and Methods {#s2}
=====================

Ethics Statement {#s2a}
----------------

This study was approved by the institutional review board of Nanjing Medical University. The design and performance of current study involving human subjects were clearly described in a research protocol. All participants were voluntary and would complete the informed consent in written before taking part in this research.

Study subjects {#s2b}
--------------

A total of 1792 breast cancer cases and 1867 cancer-free controls were included in the current study, which has been described previously [@pone.0066519-Chen1]. In brief, all of the breast cancer cases were consecutively recruited, without restrictions of age or histological type, from the First Affiliated Hospital of Nanjing Medical University, the Cancer Hospital of Jiangsu Province and the Gulou Hospital, Nanjing, China, from Jan 2004 to April 2010. These breast cancer patients were newly diagnosed and histopathologically confirmed. Those who had a history of cancer, metastasized cancer from other organs, radiotherapy or chemotherapy were excluded from the case group. All of the cancer-free women controls were randomly selected from more than 30 000 participants in a community-based screening program conducted in Jiangsu province, China. These controls were frequency-matched to the cases on age (5-year interval) and residential area (urban or rural) and collected at the same period as the patients were recruited. All of the cases and the controls were genetically unrelated, ethnic Han Chinese women. After the informed consent was obtained from each participant, a structure questionnaire was completed face-to-face by trained interviewers to collect individual information including demographic data, menstrual and reproductive history, environmental exposure, history of benign breast disease and family history of breast cancer in first-degree relatives (parents, siblings, and children). After the interview, approximately 5-ml of venous blood was collected from each subject. The estrogen receptor (ER) and progesterone receptor (PR) status determined by immunohistochemistry examinations of breast tumors were obtained from the medical records of patients in the hospitals.

Genotyping {#s2c}
----------

Genotyping was performed using the TaqMan allelic discrimination assay on the platform of 7900HT Real-time PCR System (Applied Biosystems, Foster City, CA) without knowing the subjects' status (case or control). Two negative controls included in each 384-well reaction plate were used for quality control and the genotyping results were determined by using SDS 2.3 Allelic Discrimination Software (Applied Biosystems).

Statistical analyses {#s2d}
--------------------

Hardy--Weinberg equilibrium for the distribution of each single nucleotide polymorphism (SNP) was evaluated using the goodness-of-fit χ^2^ test by comparing the observed genotype frequencies with the expected ones among the controls. Differences between the cases and the controls on the demographic characteristics, selected variables and frequencies of the genotypes were analyzed by using the Student's t test (for continuous variables) and χ^2^ test (for categorical variables). Logistic regression analyses were employed to evaluate the associations between SNPs and the risk of breast cancer and to estimate the odds ratios (ORs) and their 95% confidence intervals (CIs) with adjustment for age, age at menarche and menopausal status. The heterogeneity of associations between subgroups was assessed using the χ^2^-based Q-test. All of the statistical analyses were performed with Statistical Analysis System software (9.1.3; SAS Institute, Cary, NC, USA).

Results {#s3}
=======

Characteristics of the 1792 breast cancer cases and the 1867 cancer-free controls are presented in [Table 1](#pone-0066519-t001){ref-type="table"}. The age between cases and controls was comparable (*P*\>0.05). The breast cancer cases showed an earlier age at menarche (*P*\<0.05), a later age at first live birth (*P*\<0.05) and different distribution of menopausal status (*P*\<0.05) when compared with the controls. Among the 1,792 breast cancer subjects, 803 (55.5%) cases were ER positive while 810 (56.1%) cases were PR positive.

10.1371/journal.pone.0066519.t001

###### Distributions of select variables between breast cancer cases and cancer-free controls.

![](pone.0066519.t001){#pone-0066519-t001-1}

  Variables                                                                      Cases (N = 1792)   Controls (N = 1867)   *P* value
  ----------------------------------------------------------------------------- ------------------ --------------------- -----------
  Age, years (mean±s.d.)                                                           50.69±11.38          50.01±12.07         0.077
  Age at menarche, years (mean±s.d.)[a](#nt101){ref-type="table-fn"}                15.21±1.90          16.05±1.86         \<0.001
  Age at first live birth, years (mean±s.d.)[b](#nt102){ref-type="table-fn"}        25.60±3.32          24.51±3.03         \<0.001
  Age at natural menopause, years (mean±s.d.)[c](#nt103){ref-type="table-fn"}       49.78±3.45          49.42±3.84          0.051
  Menopausal status                                                                                                        \<0.001
  Premenopausal                                                                        850                  967          
  Natural menopausal                                                                   765                  850          
  Unnatural menopausal                                                                 142                  25           
  Estrogen receptor (ER)                                                                                                 
  Positive                                                                             803                               
  Negative                                                                             643                               
  Progesterone receptor (PR)                                                                                             
  Positive                                                                             810                               
  Negative                                                                             634                               

Age at menarche information was available in 1755 breast cancer cases and 1858 controls;

Age at first live birth information was available in 1680 breast cancer cases and 1815 controls; 65 subjects were nulliparous while 99 were with missing information;

Age at natural menopause information was available in 743 breast cancer cases and 809 controls.

The genotype distributions of the 3 SNPs in cases and controls and their associations with breast cancer risk were summarized in [Table 2](#pone-0066519-t002){ref-type="table"}. The observed genotype frequencies of 3 SNPs followed Hardy--Weinberg equilibrium in the controls (*P*\>0.05 for all SNPs). Significant associations were observed between rs10771399 at 12p11 and rs1292011 at 12q24 and breast cancer risk (*P* = 0.010 and 4.50×10^−3^, respectively). The G allele of rs10771399 and the G allele of rs1292011 were associated with a decreased risk of breast cancer (per-allele OR = 0.85, 95% CI: 0.76--0.96, *P* = 0.010; and per-allele OR = 0.84, 95% CI: 0.76--0.95, *P* = 4.50×10^−3^, respectively), which are consistent with those reported by Maya et al.[@pone.0066519-Ghoussaini1]. However, no significant association was observed between rs2823093 at 21q21 and breast cancer risk.

10.1371/journal.pone.0066519.t002

###### The associations of three loci at 12p11, 12q24 and 21q21 with breast cancer risk.

![](pone.0066519.t002){#pone-0066519-t002-2}

  Location                       Locus                      MAF [a](#nt104){ref-type="table-fn"}   Cases (N = 1792)   Controls (N = 1867)   OR(95%CI) [b](#nt105){ref-type="table-fn"}   *P* [b](#nt105){ref-type="table-fn"}                                   
  ---------- --------------------------------------------- -------------------------------------- ------------------ --------------------- -------------------------------------------- -------------------------------------- ------------------ ------------- --
  12p11                     rs10771399 A\>G                             0.258/0.125                                                                                                                                                                             
                                  AA                                                                     1145                65.69                             1145                                     62.23                         1.00                      
                                  AG                                                                     536                 30.75                             602                                      32.72                   0.89(0.77--1.04)      0.146     
                                  GG                                                                      62                 3.56                               93                                       5.05                   0.63(0.44--0.89)   9.24×10^−3^  
              Per allele [c](#nt106){ref-type="table-fn"}                                                                                                0.85(0.76--0.96)                               0.010                                                   
  12q24                     rs1292011 A\>G                              0.233/0.392                                                                                                                                                                             
                                  AA                                                                     1080                61.36                             1036                                     56.27                         1.00                      
                                  AG                                                                     598                 33.98                             695                                      37.75                   0.83(0.72--0.96)      0.013     
                                  GG                                                                      82                 4.66                              110                                       5.98                   0.75(0.55--1.02)      0.064     
              Per allele [c](#nt106){ref-type="table-fn"}                                                                                                0.84(0.76--0.95)                            4.50×10^−3^                                                
  21q21                     rs2823093 G\>A                              0.042/0.300                                                                                                                                                                             
                                  GG                                                                     1645                92.52                             1683                                     92.22                         1.00                      
                                  AG                                                                     130                 7.31                              137                                       7.51                   0.97(0.75--1.26)      0.843     
                                  AA                                                                      3                  0.17                               5                                        0.27                   0.83(0.18--3.90)      0.817     
              Per allele [c](#nt106){ref-type="table-fn"}                                                                                                0.97(0.76--1.24)                               0.795                                                   

Minor allele frequency between Asian/European population from 1000 Genomes project;

Adjusted for age, age at menarche and menopausal status;

Derived from additive model.

We further evaluated the associations of rs10771399 and rs1292011 on breast cancer risk in subgroups stratified by age, age at menarche and first live birth, and menopausal status (premenopausal and natural menopausal). As shown in [Table 3](#pone-0066519-t003){ref-type="table"}, there was no significant difference between subgroups for associations of rs10771399 and rs1292011 with breast cancer risk (*P* for heterogeneity \>0.05). Similar per-allele ORs were observed between ER/PR positive and negative breast cancer for both SNPs.

10.1371/journal.pone.0066519.t003

###### Stratified analysis on the associations of rs10771399 at 12p11 and rs1292011 at 12q24 with breast cancer risk.

![](pone.0066519.t003){#pone-0066519-t003-3}

  Characteristics                                   rs10771399   rs1292011                                                                           
  ------------------------------------------------ ------------ ------------ ------------------ ------- ------------ ------------ ------------------ -------
  Age                                                                                                                                                
  \<50                                              573/267/27   622/306/51   0.89(0.75--1.05)   0.375   515/317/44   547/370/61   0.91(0.78--1.07)   0.185
  ≥50                                               572/269/35   523/296/42   0.80(0.67--0.95)           565/281/38   489/325/49   0.78(0.66--0.92)  
  Age at menarche                                                                                                                                    
  \<15                                              443/197/32   237/126/25   0.84(0.68--1.03)   0.927   408/243/25   234/129/26   0.92(0.74--1.14)   0.374
  ≥15                                               679/328/27   905/472/66   0.85(0.73--0.98)           652/339/57   797/562/84   0.82(0.72--0.94)  
  Age at first live birth                                                                                                                            
  \<25                                              389/179/26   572/293/46   0.90(0.75--1.09)   0.471   372/200/31   532/332/47   0.91(0.76--1.08)   0.162
  ≥25                                               682/328/29   544/289/45   0.82(0.69--0.97)           649/352/47   476/342/61   0.77(0.66--0.90)  
  Menopausal status                                                                                                                                  
  Premenopausal                                     548/255/25   592/313/53   0.80(0.68--0.95)   0.497   503/290/42   541/353/65   0.89(0.76--1.04)   0.242
  Postmenopausal[c](#nt109){ref-type="table-fn"}    490/227/28   521/274/37   0.88(0.73--1.05)           480/241/31   465/323/44   0.77(0.65--0.92)  
  ER status                                                                                                                                          
  Positive                                          505/247/27                0.86(0.74--1.01)   0.992   491/259/36                0.82(0.71--0.95)   0.787
  Negative                                          408/201/21                0.86(0.73--1.02)           390/216/29                0.85(0.72--0.99)  
  PR status                                                                                                                                          
  Positive                                          518/248/25                0.84(0.72--0.98)   0.709   504/253/38                0.80(0.70--0.94)   0.574
  Negative                                          397/196/23                0.88(0.74--1.04)           377/220/27                0.86(0.73--1.01)  

Adjusted for age, age at menarche, menopausal status where appropriate;

*P* for heterogeneity;

Postmenopausal status for natural menopause.

Discussion {#s4}
==========

In this study, we evaluated the associations of genetic variants at 12p11 (rs10771399), 12q24 (rs1292011) and 21q21 (rs2823093) with breast cancer susceptibility in an independent case--control study with 1792 breast cancer cases and 1867 controls in a Chinese population. We found that rs10771399 and rs1292011 but not rs2823093 were significantly associated with altered risk of breast cancer in our population. The OR of 0.85 for rs10771399 in this Chinese population was similar to those observed in European populations initially reported by Maya *et al.* (OR = 0.85) [@pone.0066519-Ghoussaini1] and subsequently confirmed by Antonis *et al.* (OR = 0.87) [@pone.0066519-Antoniou1]. Of note, we detected a more protective effect of rs10771399 in our population (OR = 0.85) than that reported by Maya *et al.* (OR = 0.92). These findings provided new evidence for the usefulness of the breast cancer susceptibility loci at 12p11 and 12q24 in multiple populations with various descents.

Since rs10771399 was a proxy of 12p11 region, we further functionally annotated the linkage disequilibrium (LD) block containing rs10771399 using the UCSC genome browser, and found that none of known genes overlapped with this region ([Figure S1](#pone.0066519.s001){ref-type="supplementary-material"}). The nearest gene *PTHLH* encodes a protein that regulates endochondral bone development and epithelial-mesenchymal interactions during the formation of the mammary glands, whose receptor is responsible for most cases of humoral hypercalcemia of malignancy [@pone.0066519-Suva1]. This gene had been approved to be involved in the metastasis of breast cancer [@pone.0066519-Kakonen1]. We searched SNPs in strong LD (r^2^\>0.8) with rs10771399 based on CHB/JPT data of 1000 Genome pilot ([Table S1](#pone.0066519.s003){ref-type="supplementary-material"}), and predicted the biological functions of these variants using an online tool, RegulomeDB [@pone.0066519-Boyle1]. As shown in [Table S1](#pone.0066519.s003){ref-type="supplementary-material"}, three SNPs (rs788463, rs10843066 and rs7957915) were predicted to be in regulatory elements and likely to affect binding of transcriptional factors. For example, rs788463 is in 2.4 kb upstream of the lead SNP rs10771399 and in complete LD (r^2^ = 1.0) with rs10771399. Analyses of DNase Footprinting and Position-Weight Matrix (PWM) suggest that rs788463 is in the binding sites of transcriptional factors Osf2, C/EBP and C/EBPalpha. ChIP-seq data suggests this variant located at sites of multiple histone modification marks, including H3k27me3, H3k4me1 and H3k4me2. Taken together, these evidences indicate that genetic variants at 12p11 (such as rs788463) may affect the binding sites of transcriptional factors (such as C/EBP), modify the function of regulatory elements and finally involve in the development of breast cancer. However, the potential target genes are unclear and the above statements also need to be experimentally validated in the future.

Similarly, we also functionally annotated the LD block containing rs1292011 at 12q24 ([Figure S2](#pone.0066519.s002){ref-type="supplementary-material"}) and performed functional prediction for those SNPs in strong LD with rs1292011 (r^2^\>0.8) ([Table S2](#pone.0066519.s004){ref-type="supplementary-material"}). There are no genes in the LD region of rs1292011. The variant rs1391721, which is close to lead SNP rs1292011 (390 bp upstream) and highly correlated with it (r^2^ = 0.96), implies a functional potential in effecting the combination between transcription factors and their binding site. This variant falls on a position within a footprint containing an Evi-1 and GATA-1/2/3 motifs in MCF-7 cell line and substantially affect footprinting of these motifs, resulting in allelic imbalance in chromatin accessibility. Again, these evidences are kind of bioinformatics prediction and functional experiments are warranted to validate these insights.

We did not observe a significant evidence of association between rs2823093 and breast cancer risk in our study. In the study of Maya *et al.* [@pone.0066519-Ghoussaini1], they also reported a negative association of rs2823093 in women of Asian ancestry (OR = 1.14, 95%CI = 0.93--1.40) from BCAC (Breast Cancer Association Consortium). Such discrepancy is common between different populations. For example, with a consortium effort including 23637 breast cancer patients and 25579 controls of East Asian ancestry, Zheng *et al.* [@pone.0066519-Zheng2] investigated 67 independent susceptibility loci of breast cancer identified by GWAS primarily in European-ancestry populations and found 31 loci at *P*\<0.05 in a direction consistent with that reported previously. In terms of the inconsistence of rs2823093 in this study, one of the explanations is the genetic heterogeneity between populations that the identified SNP rs2823093 may be a good proxy of causal variants at 21q21 in population of European descent but poor in Asians. Moreover, as shown in [Table 2](#pone-0066519-t002){ref-type="table"}, in contrast to the other two replicated SNPs, the minor allele frequency of rs2823093 is lower in Asian population (MAF =  0.042) than those in population of European descent (MAF =  0.300), which also reflects the ethnical difference and may result in a low statistical power in this study. For another explanation, the locus of 21q21 may be out of effect in Asian women and inactive in the absence of a specific exposure in Asians, which, however, is common to European women. Taken together, discrepancy between different ethnicities for association between genetic variants and breast cancer risk could be explained partly by the different genetic background. Other possible explanations also include disease heterogeneity, study design and sample size. Well-designed fine-mapping studies with large sample size following resequencing this region may help to clearly evaluate the role of 21q21 in breast cancer development in populations of non-European descent.

In summary, our study evaluated three new breast cancer loci in a Chinese population that were identified in populations of European descent. Our results suggest that genetic variants at 12p11 and 12q24, tagged by rs10771399 and rs1292011, respectively, may also play an important role in the susceptibility of breast cancer in Chinese women. Further studies are warranted to clarify the biological mechanisms of these two loci with breast cancer risk and determine the causal variants in breast carcinogenesis.
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